TIDMGDR
RNS Number : 6251T
Genedrive PLC
16 October 2017
For release: 16 October 2017
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
genedrive plc ("genedrive" or the "Company")
genedrive signs distribution agreement with Sysmex Europe
GmbH("Sysmex Europe")
Sysmex Europe to target commercial HCV opportunity in Africa
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, today announces that it has signed a distribution
agreement with Sysmex Europe GmbH, a subsidiary of Sysmex
Corporation, a world leader in clinical laboratory systemization
and solutions, for the Genedrive(R) HCV ID Kit and Genedrive(R)
platform in the EMEA region with an initial focus on Africa.
genedrive and Sysmex Europe anticipate commercialisation beginning
in the coming months targeting end users in decentralised
laboratories in multiple countries in Africa, with the rest of the
EMEA region to follow.
With the advent of new 'curative' direct acting antiviral
treatments for Hepatitis C (HCV), genedrive and Sysmex Europe
believe that there is a major opportunity to support tackling the
global burden of the disease if accurate, decentralised diagnostics
can be used to identify those living with HCV and give them access
to therapy. genedrive's HCV test is the first to market as a
decentralised qualitative molecular HCV test for use at the point
of need. This agreement follows the recent CE-IVD Certification
from the EU for Genedrive(R) HCV ID Kit, a qualitative molecular
assay for HCV.
genedrive will retain responsibility for product development,
quality management, and manufacturing while Sysmex Europe will be
responsible for sales, marketing, customer support and distribution
activities across the EMEA region. Working together, the companies
will now focus on securing the required regulatory approvals in
individual territories of Africa and genedrive anticipates
commercial traction during the 2017/2018 financial year.
"We are very pleased to have Sysmex as our first commercial
partner for our HCV test, and our agreement represents an important
step to provide access to Genedrive(R) across target countries in
the African regions," said David Budd, CEO of genedrive plc. He
added, "Sysmex is a highly respected global organisation with the
experience and networks needed to market and commercialise our
products."
Matthias Voelkel, Senior Executive Officer of Sysmex Europe GmbH
stated, "With this agreement Sysmex further expands its portfolio
of products to meet important diagnostic needs in Africa. In line
with our company's mission of 'Shaping the advancement of
healthcare', we as a company are committed to address the specific
challenges of this region. We expect that providing healthcare
professionals with a quick diagnostic result in a decentralised
setting will allow them to further improve the management of
Hepatitis C infections."
Genedrive(R) HCV ID Kit is a qualitative HCV assay, providing
results within 90 minutes and the assay is designed for use in a
decentralised testing environment. It is performed on the company's
portable molecular diagnostics platform, Genedrive(R).
The person responsible for the release of this announcement on
behalf of the Company is Matthew Fowler, Chief Financial
Officer.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Sysmex Europe GmbH
Fernando Andreu: Senior Executive Officer +49 40 527 260
Jens Behrens: Director, Marketing Communications
Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF test have been
launched in India and a Genedrive(R) HCV test has received CE-IVD
Certification.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Sysmex Europe
Sysmex Europe GmbH (SEG), located near Hamburg, Germany, is a
subsidiary of the Sysmex Corporation from Kobe, Japan. From our
Hamburg offices - designated a Great Place to Work(R) in 2014 and
2016 - we serve our affiliates, distributors and customers
throughout EMEA - Europe, the Middle East and Africa. Globally we
employ around 8000 staff, of whom 1300 work in the EMEA region.
Sysmex is the global leader in haematology and a renowned
specialist in haemostasis, urinalysis, and laboratory automation.
As our expertise in the interdependency of disease and medical
disciplines grows, we are growing to cover other pressing areas
such as oncology, flow cytometry, liquid biopsy and essential
healthcare in resource-poor regions. This is allowing us to deliver
clinical value that primary healthcare workers such as physicians,
surgeons and other specialists can use directly to deliver better
diagnostics, treatment and monitoring, and so improve the quality
of life of their patients.
Everything we do is driven by a single mission: Shaping the
advancement of healthcare.
For more information about Sysmex Europe, please visit
www.sysmex-europe.com, and for details on Sysmex Africa
www.sysmex.co.za
About Hepatitis C
Hepatitis C (HCV) is an international public health challenge,
comparable to other major communicable diseases, including HIV,
tuberculosis and malaria. It is estimated that 150-200 million
people, or approximately 3% of the world's population, are living
with chronic HCV, and more than 350,000 people die yearly from HCV
related diseases. In 2016, WHO published the first global health
sector strategy on Hepatitis with a goal of eliminating viral
hepatitis as a major public health threat by 2030. New oral,
well-tolerated treatment regimens can achieve cure rates of over
90% however access to rapid, inexpensive and accurate diagnostics
are a critical bottleneck that must be addressed to eradicate
HCV.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRVELFFDBFZFBB
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024
